FDA Clears $40 Generic HIV Prevention Shot for Overseas UseAffordable HIV Prevention Takes a Major Step ForwardFDA’s Generic HIV Shot Approval Tests the Balance Between Access and Patents
The FDA granted tentative approval on November 2 to Dr. Reddy’s Laboratories’ generic lenacapavir, a twice-yearly HIV-prevention injection intended for 120 low- and middle-income countries.The FDA tentatively approved Dr. Reddy’s $40-a-year generic HIV prevention shot on November 2, opening a path to wider access in 120 low- and middle-income countries.The FDA tentatively approved Dr. Reddy’s generic HIV-prevention injection on November 2 for overseas markets, where it is expected to cost $40 per person annually.